Crinetics director sells 6,900 shares under plan

Crinetics Pharmaceuticals director Stephanie Okey reported selling a total of 6,900 shares of Common Stock in open-market transactions.

Rhea-AI Filing Summary

Crinetics Pharmaceuticals director Stephanie Okey reported selling a total of 6,900 shares of Common Stock in open-market transactions. The sales on June 17, 2026 were executed under a pre-arranged Rule 10b5-1 trading plan, at volume-weighted average prices of $35.62 and $36.22 per share.

Insider Trade Summary 10b5-1

Net Seller: 6,900 shares

Net Sell 2 txns

Insider Okey Stephanie

Role Director

Sold 6,900 shs ($246K)

Type	Security	Shares	Price	Value
Sale	Common Stock	6,292	$35.62	$224K
Sale	Common Stock	608	$36.22	$22K

Holdings After Transaction: Common Stock — 6,400 shares (Direct)

Footnotes (3)

1. F1. The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2025.
2. F2. The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sale price of $35.62 per share. The range of sale prices on the transaction date was $35.19 to $36.06. Detailed information on the exact number of shares can be obtained from the Issuer upon request.
3. F3. The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sale price of $36.22 per share. The range of sale prices on the transaction date was $36.19 to $36.29. Detailed information on the exact number of shares can be obtained from the Issuer upon request.

Key Figures

Shares sold: 6,900 shares VWAP sale price 1: $35.62 per share VWAP sale price 2: $36.22 per share +2 more

5 metrics

Shares sold 6,900 shares Total Common Stock sold by director in Form 4

VWAP sale price 1 $35.62 per share Volume-weighted average price for 6,292-share sale

VWAP sale price 2 $36.22 per share Volume-weighted average price for 608-share sale

Transaction date June 17, 2026 Date of reported open-market sales

Trading plan adoption date November 19, 2025 Adoption date of Rule 10b5-1 plan

Key Terms

Rule 10b5-1 trading plan, volume weighted average sale price, open market transactions, Common Stock

4 terms

Rule 10b5-1 trading plan regulatory

"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

volume weighted average sale price financial

"with a volume weighted average sale price of $35.62 per share"

open market transactions financial

"The common stock was sold by the Reporting Person in open market transactions on the transaction date"

Open market transactions are the buying and selling of a company’s shares or other securities conducted on public exchanges or through the wider market rather than through private deals or negotiated placements. They matter to investors because these trades change supply and demand in real time—like shoppers affecting a store’s inventory—and so can move prices, signal management or investor sentiment, affect liquidity, and alter ownership stakes that influence future returns and risk.

Common Stock financial

"The common stock was sold by the Reporting Person in open market transactions"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Crinetics (CRNX) disclose in this Form 4?

Crinetics Pharmaceuticals disclosed that director Stephanie Okey sold a total of 6,900 shares of Common Stock in open-market transactions on June 17, 2026, according to the Form 4 insider trading report.

How many Crinetics (CRNX) shares did director Stephanie Okey sell and at what prices?

Director Stephanie Okey sold 6,900 shares of Crinetics Common Stock. The Form 4 reports volume-weighted average sale prices of $35.62 per share for 6,292 shares and $36.22 per share for 608 shares.

Were the recent Crinetics (CRNX) insider sales made under a Rule 10b5-1 plan?

Yes. The Form 4 states the sale was effected automatically under a Rule 10b5-1 trading plan adopted by Stephanie Okey on November 19, 2025, indicating the transactions were pre-planned rather than discretionary market-timing trades.

What type of transactions did the Crinetics (CRNX) Form 4 report?

The Form 4 reports open-market sales of Crinetics Common Stock. Both transactions are coded “S”, described as sale in open market or private transaction, and are classified as non-derivative equity trades by the reporting person.

What price ranges applied to the Crinetics (CRNX) insider share sales?

The filing notes volume-weighted average prices with ranges. One sale had an average of $35.62 per share within a $35.19–$36.06 range, and the other averaged $36.22 per share within a $36.19–$36.29 range.

Who is the reporting person in the latest Crinetics (CRNX) Form 4 filing?

The reporting person is Stephanie Okey, identified in the Form 4 as a director of Crinetics Pharmaceuticals, Inc. The reported transactions involve her direct ownership of the company’s Common Stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/18/2026 - 05:23 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Okey Stephanie

(Last) (First) (Middle)

C/O CRINETICS PHARMACEUTICALS, INC.

6055 LUSK BOULEVARD

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Crinetics Pharmaceuticals, Inc. [ CRNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/17/2026		S		6,292(1)	D	$35.62(2)	7,008	D
Common Stock	06/17/2026		S		608(1)	D	$36.22(3)	6,400	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2025.

2. The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sale price of $35.62 per share. The range of sale prices on the transaction date was $35.19 to $36.06. Detailed information on the exact number of shares can be obtained from the Issuer upon request.

3. The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sale price of $36.22 per share. The range of sale prices on the transaction date was $36.19 to $36.29. Detailed information on the exact number of shares can be obtained from the Issuer upon request.

Remarks:

	/s/ Tobin Schilke, as attorney-in-fact	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)